Literature DB >> 16004683

Emerging guidelines for use of NSAID therapy to optimize cataract surgery patient care.

T P O'Brien1.   

Abstract

This analysis provides guidelines for the proper use of topical ophthalmic nonsteroidal anti-inflammatory drugs (NSAIDs), discusses their effect on inflammation, and their role in the prevention of cystoid macular edema (CME). A novel treatment strategy is presented for recommended topical ophthalmic NSAID dosing in patient populations based on risk factors for CME. The article reviews current topical ophthalmic NSAIDs, as well as a newest generation of pro-drug NSAIDs. In addition, combination therapy of NSAIDs and corticosteroids are discussed, along with a general review of therapeutic guidelines for dosing regimens, and benefits and risks of therapy. The goal of this analysis is to provide a suggested therapeutic regimen with topical NSAIDs to assist in achieving optimal clinical and functional outcomes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16004683     DOI: 10.1185/030079905X50651

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  26 in total

1.  Comparison of Preoperative Topical Dexamethasone Phosphate Versus Ketorolac Tromethamine in Maintaining Intraoperative Mydriasis During Small Incision Cataract Surgery.

Authors:  Ashok Kumar Sharma; Hans Raj Sharma; Rajni Sharma; Amrita Singh
Journal:  J Clin Diagn Res       Date:  2016-05-01

Review 2.  Ketorolac 0.45% ophthalmic solution.

Authors:  Paul L McCormack
Journal:  Drugs Aging       Date:  2011-07-01       Impact factor: 3.923

3.  Ocular penetration and anti-inflammatory activity of ketorolac 0.45% and bromfenac 0.09% against lipopolysaccharide-induced inflammation.

Authors:  L David Waterbury; Danielle Galindo; Linda Villanueva; Cathy Nguyen; Milan Patel; Lisa Borbridge; Mayssa Attar; Rhett M Schiffman; David A Hollander
Journal:  J Ocul Pharmacol Ther       Date:  2011-02-25       Impact factor: 2.671

Review 4.  Cataract surgery and nonsteroidal antiinflammatory drugs.

Authors:  Richard S Hoffman; Rosa Braga-Mele; Kendall Donaldson; Geoffrey Emerick; Bonnie Henderson; Malik Kahook; Nick Mamalis; Kevin M Miller; Tony Realini; Neal H Shorstein; Richard K Stiverson; Barbara Wirostko
Journal:  J Cataract Refract Surg       Date:  2016-09       Impact factor: 3.351

5.  Treatment of cystoid macular edema with the new-generation NSAID nepafenac 0.1%.

Authors:  Seenu M Hariprasad; Levent Akduman; Joseph A Clever; Michael Ober; Franco M Recchia; William F Mieler
Journal:  Clin Ophthalmol       Date:  2009-06-02

6.  Analgesic and anti-inflammatory effectiveness of nepafenac 0.1% for cataract surgery.

Authors:  M Nardi; C Lobo; A Bereczki; J Cano; E Zagato; S Potts; G Sullins; R Notivol
Journal:  Clin Ophthalmol       Date:  2007-12

7.  Management of ocular inflammation and pain following cataract surgery: focus on bromfenac ophthalmic solution.

Authors:  Hyung Cho; Kenneth J Wolf; Eric J Wolf
Journal:  Clin Ophthalmol       Date:  2009-06-02

8.  Diabetic cataract-pathogenesis, epidemiology and treatment.

Authors:  Andreas Pollreisz; Ursula Schmidt-Erfurth
Journal:  J Ophthalmol       Date:  2010-06-17       Impact factor: 1.909

9.  The effect of topical sodium diclofenac on macular thickness in diabetic eyes after phacoemulsification: a randomized controlled trial.

Authors:  Morteza Entezari; Alireza Ramezani; Homayon Nikkhah; Mehdi Yaseri
Journal:  Int Ophthalmol       Date:  2016-03-14       Impact factor: 2.031

Review 10.  The role of NSAIDs in the management of postoperative ophthalmic inflammation.

Authors:  Joseph Colin
Journal:  Drugs       Date:  2007       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.